We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Bayer to Sell Diagnostics Division to Siemens for $5.3 Billion

By HospiMedica staff writers
Posted on 07 Jul 2006
Following on the heels of its successful takeover of drug company Schering AG (Berlin, Germany), the Bayer Group (Leverkusen, Germany) has taken a move that will enable still more concentration on pharmaceuticals by announcing plans to sell its diagnostics division to Siemens AG (Munich, Germany) for about U.S.$5.3 billion.

"We are concentrating on pharmaceuticals for both humans and animals, and products that can be promoted directly to patients,” explained Werner Wenning, chairman of the management board at Bayer AG.

The Diabetes Care Division will not be included in the sale nor will the diagnostic imaging business of Schering AG. More...
However, the systems business of the Diagnostics Division, with its emphasis on hardware, information technology (IT) networking, and laboratory equipment, is subject to different success factors, according to Bayer, and therefore will be included in the sale.

"Bayer Healthcare Diagnostics has grown considerably faster than the market in terms of earnings and profitability over the past three years,” said Arthur Higgins, chairman of the board of management of Bayer HealthCare AG. "So now is the right time to divest this successful business and thereby add value for the Bayer Group. Siemens is the ideal company to continue developing Bayer HealthCare Diagnostics as a core business.”

"With this acquisition we are continuing to consistently pursue our strategy of building the industry's first integrated diagnostics company that combines diagnostic imaging, laboratory diagnostics, and clinical information technology under one roof right along the value chain,” observed Erich Reinhardt, CEO and president of Siemens Medical Solutions.

The transaction will also help Bayer to reduce some of the debt incurred for the financing and acquisition of Schering.



Related Links:
Siemens AG
Bayer AG

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Gas Analyzer
GE SAM
New
Radiology Monitor
Barco MDNC-12130 Nio Fusion 12MP Radiology Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.